"目錄號: HY-13750
Ebselen是HIV-1復制的小分子抑制劑, 是一種抗氧化藥物。
相關(guān)產(chǎn)品
Cycloheximide-TAK-242-LY294002-3-Methyladenine-(+)-JQ-1-SB 203580-SP600125-U0126-Enzalutamide-Actinomycin D-Olaparib-Doxorubicin hydrochloride-Dorsomorphin dihydrochloride-Mitomycin C-Bortezomib-
生物活性
Description
Ebselen is a small-molecule capsid Inhibitor of HIV-1 replication.Target:Ebselen is an organoselenium compound, as an inhibitor of HIV-1 capsid CTD dimerization. Ebselen inhibits early viral postentry events of the HIV-1 life cycle by impairing the incoming capsid uncoating process. [1] Ebselen is a non-toxic seleno-organic drug with anti-inflammatory and antioxidant properties. Ebselen is an inhibitor of inositol monophosphatase (IMPase). Ebselen permeates the blood-brain barrier and inhibits endogenous inositol monophosphatase in mouse brain. [2]
Clinical Trial
University of Oxford-Stanley Medical Research Institute-Sound Pharmaceuticals, Incorporated
Bipolar Disorder-Bipolar Disorder, Manic
June 30, 2017
Phase 2
Brigham and Women's Hospital
Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus
May 1999
Phase 2-Phase 3
Sound Pharmaceuticals, Incorporated-Medical University of South Carolina-Cystic Fibrosis Foundation Therapeutics
Ototoxicity
May 2017
Phase 1-Phase 2
Sound Pharmaceuticals, Incorporated
Meniere's Disease
December 2015
Phase 1-Phase 2
Sound Pharmaceuticals, Incorporated
Hearing Loss-Cancer
May 2006
Phase 1
Sound Pharmaceuticals, Incorporated
Noise Induced Hearing Loss
September 2016
Phase 2
Sound Pharmaceuticals, Incorporated-University of Florida
Temporary Auditory Threshold Shift
September 2011
Phase 2
Sound Pharmaceuticals, Incorporated-VA Puget Sound Health Care System
Lung Cancer-Head and Neck Cancer-Hearing Loss-Ototoxicity-Tinnitus-Neuropathy
August 2016
Phase 2
View MoreCollapse
References
